Therefore, we compared the effects of ITGAV-KD and the pharmacological inhibition of ITGAV/ITGB3 and ITGAV/ITGB5 complexes using ITGAV heterodimer inhibitor cilengitide, a molecule36 originally developed for the treatment of glioblastoma. The gene discussed is ITGB3; the disease is glioblastoma.